You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Novel Inhibitors of Pim Protein Kinases

    SBC: VORTEX BIOTECHNOLOGY CORPORATION            Topic: N/A

    DESCRIPTION (provided by applicant): There is a growing body of evidence that implicates the protein kinase Pim-1 as a major driver of prostate cancer progression, and perhaps response to chemotherapy. Pim-1 is overexpressed in early prostate intraepithelial neoplasia and metastatic prostate cancer, and its levels predict response to therapy. Pim-1-overexpressing mouse prostate stem cells demonstr ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  2. Tooth Phone Auditory Device TPAD

    SBC: Audiodontics LLC            Topic: N/A

    DESCRIPTION (provided by applicant): TOPIC - Tooth Phone(R) Auditory Device - TPAD ABSTRACT The Tooth Phone(R) Auditory Device - TPAD is new alternative device to the only direct bone conduction hearing aid currently accepted by the Food and Drug Administration (FDA) for the treatment of certain specific types of hearing loss. Unlike the precedent FDA approved device that uses an osseointegrated i ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  3. Acid Ceramidase, Target for Cancer

    SBC: Sphingogene, Inc            Topic: N/A

    DESCRIPTION (provided by applicant): Acid ceramidase (AC) has been implicated as a novel target for cancer therapy because of its pivotal role in regulating interconversion of three key bioactive lipids; ceramide (Cer), sphingosine (Sph) and Sphingosine-1-Phosphate (S1P). It is well known that Cer functions predominantly as a tumor suppressor lipid and mediator of apoptosis following chemo and rad ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  4. New chaperones for folding and assembly of proteins

    SBC: FIDELITY SYSTEMS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): A novel approach is needed to overcome the deficiencies of protein production technology and ensure the produced enzymes fold into physiologically effective three-dimensional conformations. We discovered that incorporation of novel archaeal chaperones into a host-vector system and into in vitro enzymatic reactions helps both to recover proteins from inclusion b ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  5. Advanced Software for Enabling Quantitative 3D Stress Echocardiography

    SBC: IGI TECHNOLOGIES, INC            Topic: N/A

    DESCRIPTION (provided by applicant): Through more than 5 years of research, we have developed a new cardiovascular procedure termed quantitative three-dimensional (3D) stress echocardiography (echo). Because of exceedingly high computational demands, the procedure remains clinically nonviable despite our mature academic research. The objective of this STTR project is to remove the computation bott ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  6. Prospective/Retrospective Motion Correction System for Motion Robust Pediatric MR

    SBC: ROBIN MEDICAL INC            Topic: N/A

    DESCRIPTION (provided by applicant): A Tracked MR Hardware/Software System for Motion Robust Pediatric Magnetic Resonance Imaging This research aims to develop improved motion robust magnetic resonance imaging (MRI) technology. Magnetic resonance imaging is a powerful tool that both aids in the diagnosis of individual subjects, guides their clinical care, and provides insights into the mechanisms ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  7. TOWAR: a comprehensive Training on Women's Addiction and Recovery

    SBC: SOCIAL SOLUTIONS INTERNATIONAL            Topic: N/A

    DESCRIPTION (provided by applicant): The purpose of this Phase I Small Business Technology Transfer (STTR) proposal is to develop a woman-focused model of care specifically for use in a drug court system. Social Solutions International, Inc. (SSi), in cooperation with UCLA Integrated Substance Abuse Programs (ISAP), proposes to develop this woman-focused, innovative model of a drug court program. ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  8. Development of VPL Vaccine for RSV

    SBC: SIGMOVIR BIOSYSTEMS, INC.            Topic: NIAID

    Project Summary Human respiratory syncytial virus (RSV) is recognized as the single most important viral cause of acute respiratory disease in infants and young children worldwide. Elderly populations and immunocompromised individuals are also at significant risk for serious RSV disease. Despite this very substantial disease burden imposed by RSV worldwide, there are no vaccines available. Severa ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Non-ATP competitive inhibitors of cyclin dependent kinases as cancer therapeutics

    SBC: PPI PHARMACEUTICALS, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): As cancer is one of the leading causes of death in the United States with some sub-types remaining essentially untreatable, expansion of available drug targets will provide significant new options for the development ofmore effective antineoplastic agents. The major goal of this project is to apply a unique drug discovery strategy to cancer drug development. Th ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Developing a Nrf2 activator for the treatment of scleroderma

    SBC: CUREVEDA, LLC            Topic: NIAMS

    DESCRIPTION (provided by applicant): Scleroderma is a devastating autoimmune disease with a chronic course, involving the overproduction of collagen leading to fibrosis of the skin and connective tissues. The disease has a range of symptoms including pain,stiffness and swelling of the joints, shortness of breath and gastrointestinal complications. More than 50% of patients with the aggressive form ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government